Olumiant (baricitinib)

£1,306.70£4,455.46

Olumiant (baricitinib) is a medication used for the treatment of rheumatoid arthritis and for the treatment of moderate to severe atopic dermatitis.

On November 19, 2020 the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Olumiant (baricitinib), in combination with Veklury (remdesivir), to treat COVID-19 patients.

DISEASE INDICATIONS

Rheumatoid Arthritis

MANUFACTURER

Eli Lilly Nederland B.V.

USAGE

Oral

MEDICINE APPROVED BY

  • European Medical Agency (EMA)

  • Food and Drug Administration (FDA)

  • Therapeutic Goods Administration (TGA)

    PATIENTS HELPED

    • Over 1.2 million patients reached

    • More than 11,000 patients helped

    • 100% successful deliveries to 88 countries

This content has been reviewed by a Medical Doctor.
OLUMIANT (BARICITINIB) Package Tablets

28 tablets of 2 mg, 98 tablets of 2 mg, 28 tablets of 4 mg, 98 tablets of 4 mg

Reviews

There are no reviews yet.

Be the first to review “Olumiant (baricitinib)”

Your email address will not be published. Required fields are marked *

Shopping Cart